Next-Generation Sequencing (NGS) Market Size, Share, By Technology (Whole Genome Sequencing, Whole Exome Sequencing, RNA Sequencing, Targeted Re-sequencing and Others), By Application (Drug Discovery, Personalized Medicine & Genetic Screening, Disease Diagnosis, Agriculture & Animal Research and Others), By End User (Hospitals, Research Centers, Pharma & Biotech Firms and Others), and By Region - Trends, Analysis and Forecast till 2034

Next-Generation Sequencing (NGS) Market Size was valued at USD 11.8 Billion in 2024 and is expected to grow at a CAGR of 13.6% to reach USD 37.8 Billion by 2034

Next-generation sequencing (NGS) is a rapid, scalable, and extremely high capacity massively parallel sequencing method. Using this approach, the nucleotide order of entire genomes or specific DNA or RNA portions can be ascertained. The biological sciences have been completely transformed by NGS, which enables labs to research biological systems at a depth never before achievable and carry out a vast range of applications.

The intricate genomics inquiries of today require a level of informational depth that is beyond the capabilities of conventional DNA sequencing technologies. NGS has closed that gap and evolved into a regular instrument for answering these kinds of inquiries.

Notwithstanding the advancements in this area of study, there are still a number of obstacles to overcome in the workflow and data analysis associated with the NGS process. The primary rate-limiting step in the analysis and interpretation of NGS data is thought to be the absence of flexible in silico tools. Industry participants are currently working closely together to combine their resources in order to mine these massive, intricate databases and produce insights that are actionable and therapeutically useful.

Key Drivers of Next Generation Sequencing Market:

Increased genome mapping programs

• Assigning/locating of a specific gene to particular region of a chromosome and determining the location of and relative distances between genes on the chromosome it is known as genome mapping. Programs are performed to receive a high throughput data; thus, it acts as a driving factor.

Increased applications of next generation sequencing

• The Labs can quickly sequence whole genomes thanks to NGS. Target regions should be deeply sequenced. Quantify mRNAs for gene expression studies or use RNA sequencing (RNA-Seq) to find new RNA variations and splicing sites.

Increased healthcare expenditure

• Over the decade with advancement of technology the cost of living includes health expenditure and it has increased over the year contributing to public health domain.

Technological breakthroughs

• Many advanced technologies are used to collect high-throughput data as a result. These advancements have been beneficial to the market for saving time for processing huge amount of DNA or RNA strands and detecting them out at a time.

Restrains:

The scarcity of experienced specialists

• The market for next gen sequencing requires efficient and highly skilled professionals. Thus, it is not possible to cover it at a large-scale testing as it requires greater amount of accuracy and skills.

Ethical and regulatory limitation

• Concerns about bias and its ramifications for fiduciary duties are also raised by the use of machine learning for the sequencing and analysis of genetic data. Three primary ethical domains—privacy, informed consent, and result return—present unique issues for NGS.

The market is segmented based on Technology, Application, End-User, and Region.

Technology Insights:

• Whole Genome Sequencing: About 2% of the genome, or 60 million base pairs, are covered by whole exome sequencing. Despite making up a very minor portion of an individual's genetic makeup, this DNA contains areas that are involved in protein coding. The exome contains the majority of genetic variants that cause disease.
• Exome Sequencing: One popular next-generation sequencing (NGS) technique that entails sequencing the genome's protein-coding regions is called whole-exome sequencing. The human exome comprises around 85% of known disease-related variations, although making up less than 2% of the genome.1 This makes the approach a more affordable option than whole-genome sequencing. A wide range of applications, such as population genetics, genetic illness, and cancer research, can benefit from the effective identification of coding variations that exome sequencing employing exome enrichment can provide.
• RNA Sequencing: One technology that provides valuable insights into the transcriptome of cells is RNA sequencing, or RNA-seq. Numerous domains, including as the study of hereditary diseases and cancer biomarkers, can benefit from the application of this NGS technique. An overview of a typical RNA-seq workflow is given in this DECODED.
• Target Re-sequencing: A subset of genes or genomic areas are separated and sequenced via targeted resequencing. Next-generation sequencing (NGS) targeted techniques enable researchers to concentrate resources (time, money, and data analysis) on certain areas of interest. The exome, which is the section of the genome that codes for proteins, certain genes of interest (custom content), targets found inside genes, and mitochondrial DNA are examples of such targeted analyses.

Applications Insights:

• Drug Discovery: Target genes for upcoming drug development initiatives can be identified using NGS, which also has the ability to find several mutations linked to genetic illnesses. NGS is becoming more and more popular as the method of choice for drug target selection when compared to GWAS, which depends on proxy indicators for unidentified causative variations or genes.
• Personalized medicine: Multiple genes can be sequenced simultaneously using next-generation sequencing (NGS), which can also be used to focus medications, lower total healthcare costs, and find illness-associated variations to assist match patients to therapies or assess disease risk.
• Genetic screening: In genetic testing, a person's blood, skin, hair, or other bodily tissue is examined to check for mutations in the DNA, chromosomes, or proteins that may indicate a hereditary disorder.
• Disease Diagnosis: For the diagnosis of complex diseases that involve multiple genes, NGS is the most suitable option. These diseases include autism, connective tissue disorders, cardiomyopathies (disease of the heart muscle that impedes blood pumping), and disorders of sex development)
• Agricultural and animal research: A high-resolution picture of the genomic variation affecting phenotypic in both plants and animals can be obtained by NGS. It is helpful in the search for new markers. When dealing with smaller sample sizes, it provides an affordable substitute for microarrays.

End-User Insights:

• Hospitals: the hospitals carrying advanced technology for NGS utilize it as a disease diagnostic tool. It helps to detect the genetic disorder of the patients and also used for many other diagnostics purposes like grafting.
• Research centers: The Research centers utilize the NGS technology for many purposes like to study a new gene, to screen test all genes at one time and also to quantify a gene that is helpful for human beings.
• Pharma and biotech firms: Biotech firms are also primary user for NGS for example development of new drug that links with gene therapy .it is also used for research purposes so these firms act as an end user.

Regional Insights

• North America particularly the United States and Canada, is a significant Next Generation Sequencing Market due to strong regulatory frameworks and increasing investor demand for transparency in sustainability practices as well greater consideration for public health domain drives the market upwards.
• Asia Pacific region is rapidly growing in the Next Gen Sequencing Market due to increasing regulatory developments, investor interest, and corporate sustainability efforts. Countries like Japan, South Korea, and Australia are enhancing their cancer therapeutics and diagnostics requirements. China is also beginning to emphasize cancer diagnostics as part of its broader economic reforms.
• Europe is expected to dominate the target market growth and this region is also considered a leader in the Next Gen Sequencing Market, driven by rigorous regulations and a strong cultural emphasis on sustainability and skillful management practices.
• Latin America is emerging as a promising market for cancer diagnostics, driven by increasing awareness and regulatory initiatives. There is a growing awareness of genetic health and healthcare among businesses and investors in Latin America. This has led to increased adoption of cancer diagnostics practices.
• Middle East & Africa region is a growing interest from both regional and international investors in next generation sequencing market, driving companies to NGS tools to enhance transparency and attract investment and use for beneficial purposes.

Next-Generation Sequencing (NGS) Market Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study segmented the target market report based on Technology, Applications, End-User, and Region.

By Technology:

• Whole Genome Sequencing
• Whole Exome Sequencing
• RNA Sequencing
• Targeted Re-sequencing
• Others

By Applications:

• Drug Discovery
• Personalized Medicine
• Genetic Screening
• Disease Diagnosis
• Agriculture & Animal Research
• Others

By End-User:

• Hospitals
• Research Centers
• Pharma & Biotech Firms
• Other

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Next-Generation Sequencing (NGS) Market include Thermofischer Inc., Hoffmann-La Roche Ltd., Novartis International AG, Celgene Corporation, Johnson & Johnson, Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., Eli Lilly and Company, AbbVie Inc., and Bayer AG.

• In July 2023, the launch of the QIAseq Normalizer Kits that give researchers a fast, convenient and cost-effective method to pool different DNA libraries for best-quality results from next-generation sequencing (NGS) runs. The QIAseq Normalizer Kit speeds up equalizing DNA concentrations across NGS libraries – so-called normalization – to 30 minutes from several hours by ending the need for quantifying DNA libraries using time-intensive and expensive procedures. It is high-throughput with an optimized protocol for parallel normalization of 96 samples, automation-friendly, and works without hazardous chemicals. 
• In May 2023, Telesis Bio announced the first commercial shipment of its BioXp NGS Library Prep kit for plasmid sequencing. Leveraging this new automation capability of the BioXp platform is expected to enable researchers in high-throughput discovery workflows to reduce hands-on time, cost, and steps of NGS Library Preparation, both accelerating their time to answer and reducing barriers to access to Next-Generation Sequencing.

• Thermofischer Inc.
• Hoffmann-La Roche Ltd.
• Novartis International AG
• Celgene Corporation,
• Johnson & Johnson,
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Merck & Co. Inc.
• Eli Lilly and Company
• AbbVie Inc.
• Bayer AG